Trial Profile
A Prospective Randomized, Open-Label, Parallel-Group Comparative Study: Atorvastatin Pre-Treatment Versus Usual Care In Asian Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary)
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- Acronyms ALPACS
- Sponsors Pfizer; Viatris
- 19 May 2010 Actual patient number (499) added as reported by ClinicalTrials.gov.
- 19 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.